Selegiline News and Research

RSS

Groundbreaking study reveals most effective adjunctive drug for Parkinson's disease

The efficacy, tolerability, and safety of various anti-Parkinson's drugs.

23 Oct 2023

A scientific statement from the American Heart and Stroke Association on the prevalence, diagnosis, and management of poststroke cognitive impairment

Researchers reviewed the incidence, prevalence, diagnosis, and management of post-stroke cognitive impairment.

3 May 2023

Exploring the neuroprotective potential of cell-penetrating peptides, extracellular vesicles, and micro ribonucleic acids

In a recent review published in Biomedicines, researchers explored extracellular vesicles (EVs), cell-penetrating peptides (CPPs), and micro ribonucleic acids (miRNAs) as therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

1 Mar 2023

Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson's disease (PD) and improve long-term outcomes.

6 Mar 2017

New therapeutic targets release mechanisms in reactive astrocytes for treatment of Alzheimer's disease

Alzheimer's disease, which is the most common cause of dementia, is fatal and currently, there is no cure. In Alzheimer's disease, brain cells are damaged and destroyed, leading to devastating memory loss.

9 Jul 2014

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.

9 Sep 2011

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

Nearly three-quarters of patients with Parkinson's disease experience fatigue or excessive daytime sleepiness (EDS), but clinicians should assess both problems separately in order to improve the profession's understanding of their distinct, but overlapping, physiology. That is the key finding of a study published in the December issue of the European Journal of Neurology.

1 Dec 2010

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

Four Pharma companies underpay Medicaid rebate obligations, pay $124M to resolve allegations

Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical have entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs, the Justice Department announced today.

20 Oct 2009

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health.

14 Oct 2009

Practice parameters discuss treatment for narcolepsy, other hypersomnias of central origin

Practice parameters published in the December 1 issue of the journal SLEEP serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin, including idiopathic hypersomnia, recurrent hypersomnia and hypersomnia due to medical condition.

3 Dec 2007

Selegiline News and Research

Groundbreaking study reveals most effective adjunctive drug for Parkinson's disease

A scientific statement from the American Heart and Stroke Association on the prevalence, diagnosis, and management of poststroke cognitive impairment

Exploring the neuroprotective potential of cell-penetrating peptides, extracellular vesicles, and micro ribonucleic acids

Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

New therapeutic targets release mechanisms in reactive astrocytes for treatment of Alzheimer's disease

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

New systematic study for managing treatment-resistant bipolar depression

Four Pharma companies underpay Medicaid rebate obligations, pay $124M to resolve allegations

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Practice parameters discuss treatment for narcolepsy, other hypersomnias of central origin

Mylan granted U.S. patent for transdermal product

Parkinson's patients stomach new drug better than conventional meds

Benefits of MAO-B inhibitors are small but may be worthwhile in some patients with early Parkinson's disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News